Organon & Co. (OGN): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
OGN Stock Price Chart Interactive Chart >
OGN Price/Volume Stats
|Current price||$29.01||52-week high||$38.75|
|Prev. close||$29.23||52-week low||$27.25|
|Day high||$29.40||Avg. volume||3,871,653|
|50-day MA||$31.38||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||7.35B|
Organon & Co. (OGN) Company Bio
Organon & Co. Organon & Co. is a science-based global pharmaceutical company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. Its women's health portfolio includes Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. Its operating segments include the Organon Products segment. The Organon Products segment is engaged in developing and delivering health solutions through its portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's products segment portfolio includes: Women's Health, Biosimilars and Established Brands. Women's Health contains contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing and elonva. The Company's Biosimilars portfolio consists of three immunology products: Brenzys, Renflexis and Hadlima; and two oncology products: Ontruzant and Aybintio.
OGN Latest News Stream
|Loading, please wait...|
OGN Latest Social Stream
View Full OGN Social Stream
Latest OGN News From Around the Web
Below are the latest news stories about Organon & Co that investors may wish to consider to help them evaluate OGN as an investment opportunity.
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
JERSEY CITY, N.J. & GENEVA, Switzerland, July 27, 2021--Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor
JERSEY CITY, N.J., July 22, 2021--Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021
Neither healthcare stock has performed well so far this year.
Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive.
Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
JERSEY CITY, N.J., June 29, 2021--Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
OGN Price Returns